Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07614984 | A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004) | PHASE2 | NOT YET_RECRUITING | 750 | — | — | Jul 7, 2026 | Oct 12, 2027 | May 29, 2026 | - | — |
Blood samples will be collected at baseline and at Week 8 to assess the mean percent change from baseline in Lp(a).
Blood samples will be collected at baseline and at Week 8 to assess the mean percent change in LDL-C.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Participants will receive MK-7262 placebo + enlicitide placebo orally once daily (QD) for up to approximately 12 weeks of treatment. |
| enlicitide monotherapy | ACTIVE_COMPARATOR | Participants will receive enlicitide + MK-7262 placebo orally once daily (QD) for up to approximately 12 weeks of treatment. |
| MK-7262 monotherapy | EXPERIMENTAL | Participants will receive MK-7262 + enlicitide placebo orally once daily (QD) for up to approximately 12 weeks of treatment. |
| MK-7262 + enlicitide | EXPERIMENTAL | Participants will receive MK-7262 + enlicitide orally once daily (QD) for up to approximately 12 weeks of treatment. |
| Name | Type | Description |
|---|---|---|
| MK-7262 | DRUG | Oral Coated Tablet |
| Enlicitide | DRUG | Oral Coated Tablet |
| Placebo for MK-7262 | DRUG | Oral Coated Tablet |
| Placebo for enlicitide | DRUG | Oral Coated Tablet |
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has Lp(a) ≥ 150 nmol/L * Is receiving an optimized and stable dose of statin for ≥ 30 days with no planned additions, dose changes, or discontinuations through the duration of the study Exclusion Crite...